The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Circulating tumor cells and MRD monitoring in multiple myeloma
Luca Bertamini, MD, Erasmus MC, Rotterdam, Netherlands, discusses how circulating tumor cell (CTC) assessment could complement measurable residual disease (MRD) testing in multiple myeloma. He highlights the greater sensitivity of bone marrow MRD while noting that blood-based CTC monitoring could reduce the need for repeated marrow assessments. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
